



## OPINION

# Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: Real-life experience of implementing FOxTROT

Christopher JM Williams<sup>1,2</sup> | Rebecca Fish<sup>3,4</sup> | Lucy Akerman<sup>1</sup> | Nicholas West<sup>1,2</sup> | Damian Tolan<sup>1,2</sup> | Aaron J. Quyn<sup>1,2</sup> | Jenny F Seligmann<sup>1,2</sup>

<sup>1</sup>Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

<sup>2</sup>Leeds Institute of Medical Research, St James's, School of Medicine, University of Leeds, Leeds, UK

<sup>3</sup>Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre, Manchester, UK

<sup>4</sup>Colorectal and Peritoneal Oncology Centre, Christie NHS Foundation Trust, Manchester, UK

### Correspondence

Rebecca Fish, Colorectal and Peritoneal Oncology Centre, Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, UK.  
Email: [rebecca.fish-2@manchester.ac.uk](mailto:rebecca.fish-2@manchester.ac.uk)

### Abstract

**Aim:** The international FOxTROT trial, recently published in the Journal of Clinical Oncology is the first randomized controlled trial testing neoadjuvant chemotherapy (NAC) with oxaliplatin and 5-fluorouracil in locally advanced, but operable, colon cancer. The trial met its primary endpoint with fewer patients experiencing recurrent or residual disease at 2 years with NAC compared with the control (16.8% vs. 21.2%, risk ratio = 0.74,  $p = 0.042$ ). Translating the findings of the FOxTROT trial into improved patient outcomes is dependent on implementation of new neoadjuvant chemotherapy (NAC) pathways in colorectal cancer.

**Method:** We describe our experience implementing a novel neoadjuvant treatment pathway in colorectal cancer at a large UK teaching hospital.

**Results:** To date 64 patients have been commenced on the novel pathway following presentation and adoption of the FOxTROT trial results. We present key lessons and strategies developed across the multidisciplinary team to minimize impact on person hours, service capacity and budget, whilst building patient safety and confidence.

**Conclusion:** Use of NAC for locally advanced colon cancer has been shown to improve surgical outcomes and longer term cancer outcomes. Provision of NAC requires some modifications to current treatment pathways but can be delivered with team working and without the requirement for additional resources.

### KEYWORDS

carcinoma of the colon, chemotherapy, FOxTROT, neoadjuvant therapy

Christopher J. M. Williams and Rebecca Fish Joint first authors.

Originality: This manuscript is original and its publication does not infringe any copyright. The manuscript has not been previously published or submitted to, in whole or in part in any other journal or scientific publishing company.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Colorectal Disease* published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.

## INTRODUCTION

The international FOxTROT trial, recently published in the *Journal of Clinical Oncology*,<sup>1</sup> is the first randomized controlled trial testing neoadjuvant chemotherapy (NAC) with oxaliplatin and 5-fluorouracil in locally advanced, but operable, colon cancer. One thousand fifty three patients with operable, radiologically staged T3-T4, N0-2, M0 colon cancer were recruited from over 100 sites in the UK, Sweden and Denmark. Patients were randomized to either 6 weeks of NAC before resectional surgery followed by adjuvant chemotherapy; or to the control arm of upfront surgery followed by adjuvant chemotherapy (the duration of treatment was 18 weeks in both arms). Neoadjuvant chemotherapy was safe and, compared with standard treatment in the control arm, there was no increase in surgical complications, a higher R0 rate (95% vs. 89%,  $p < 0.001$ ) was reported, and primary and nodal pathological downstaging was achieved. The trial met its primary endpoint with fewer patients experiencing recurrent or residual disease at 2 years with NAC compared with control (16.8% vs. 21.2%, risk ratio = 0.74,  $p = 0.042$ ).

Rapid translation of these results into patient benefit is expected, particularly as the chemotherapeutic agents are already used routinely and do not incur any additional cost or toxicity. However, offering NAC as standard care for advanced colon cancer requires adaptations to current treatment pathways and therefore presents organizational challenges.

To date, the Leeds Cancer Centre, St James's University Hospital, UK, has commenced 64 patients on the novel pathway following presentation and adoption of the FOxTROT results. Here, we describe our experience and share strategies developed across the multidisciplinary team (MDT) to minimize impact on person hours, service capacity and budget, whilst building patient safety and confidence.

## THE MDT

### Key lesson: Involve the whole colon cancer MDT

Engagement and buy-in from all local MDT (tumour board) members is key to delivering NAC. Collaborative working involving the surgeon, oncologist, radiologist, pathologist and specialist nurse is critical for the success of the patient pathway (Figure 1).

### Key lesson: Specialist colorectal radiology expertise is critical

An important determinant of patient eligibility for NAC is radiological staging, so specialist radiologist input is key. Radiologists should be confident that patients considered for NAC have a cT3 or cT4 tumour and they should also be empowered to highlight, at MDT meetings, the suitability of these patients for NAC. There is no evidence base for treating borderline cT2/3, cN0 disease with NAC. These patients should proceed directly to surgery.

### What does this paper add to the literature?

Translating the findings of the FOxTROT trial into improved patient outcomes is dependent on implementation of new neoadjuvant chemotherapy (NAC) pathways in colorectal cancer. This paper provides practical guidance for the whole multidisciplinary team on how NAC can be implemented with minimal impact on service capacity and budget while protecting patient safety and confidence.

### Key lesson: Access to rapid mismatch repair testing should not be a deal-breaker

Consistent with studies of adjuvant chemotherapy,<sup>2</sup> a subgroup analysis within FOxTROT suggested a lack of survival benefit—but no harm—from NAC in patients with mismatch repair-deficient (dMMR) tumours. Mismatch repair (MMR) (or microsatellite instability) testing is recommended for all patients with colorectal cancer at the point of diagnosis<sup>3</sup> and is increasingly accessible to clinicians and patients, although the results are not universally available in time to influence decision making at the first MDT meeting. Rapid turnaround of MMR testing provides greater precision in patient selection and is recommended. However, as NAC resulted in recurrence-free survival benefit in the unselected FOxTROT population, lack of rapid MMR testing should not impede access to NAC, particularly for patients with disease distal to the splenic flexure, where the dMMR tumour rate is only 5%.


### Key lesson: Clinical nurse specialist oversight is key to a smooth and efficient patient journey

In addition to their existing roles as a primary point of contact and support for the patient, the clinical nurse specialist (CNS) coordinates the activities of the rest of the MDT to optimize progression along the treatment pathway, tracking pending results of investigations (such as MMR testing), and communicating projected operation dates to expedite decision making and planning.

## PATIENT FLOW AND FIRST CLINIC REVIEW

### Key lesson: Be flexible and respond to patient feedback when implementing pathway changes

Conventionally, the first clinic review for patients with operable colon cancer is with the colorectal surgeon and the CNS, where diagnosis and planned surgical resection are discussed. Oncology review has previously been indicated only for consideration of postoperative adjuvant chemotherapy.



**FIGURE 1** Leeds resectable colon cancer pathway. To minimize delays to chemotherapy, testing for the dihydropyrimidine dehydrogenase (DPYD) gene should be conducted as early in the pathway as feasible. chemo, chemotherapy; CNS, clinical nurse specialist; CT, computed tomography; MDT, multidisciplinary team; MMR, mismatch repair testing; NAC, neoadjuvant chemotherapy; pMMR, proficient mismatch repair.

Several models for consultations on the NAC pathway have been utilized in Leeds – each with advantages and disadvantages. It is important to reduce delays to ensure that patients receive NAC promptly. Initial oncology review is efficient but requires physician confidence in assessing symptoms of potential bowel obstruction and addressing patient queries about the likely operative plan. Additionally, patient distress can arise through receipt of an unexpected oncology clinic appointment. Such distress may be avoided through post-MDT communication from the CNS team.

As confidence has grown among the oncology and CNS teams, patients are now frequently reviewed first by oncology. When this is the case, patient feedback indicates that early discussion of the planned operation with their surgeon provides reassurance. Additionally, where there is evidence of impending obstruction, flexibility in surgical clinics and lists is required to enable defunctioning

surgery prior to commencing NAC (as per the FOxTROT protocol) or stenting. Early review by both teams has been found to improve the patient experience and best facilitate surgical prehabilitation. However, the order of oncology and surgical reviews will depend upon patient needs and local working practices.

## NEOADJUVANT CHEMOTHERAPY

### Key lesson: Clear communication between oncology and surgery minimizes delays

Where NAC is commenced, high priority is given to early provision of treatment to minimize delay. The oncologist is responsible for communicating the ideal time window for definitive surgery, including any alterations to this arising from chemotherapy toxicities.

## PROCEEDING TO SURGERY

### Key lesson: Additional post-NAC imaging may not be necessary; NAC does not place significant additional demands on surgical clinics

Initially, a post-NAC CT scan was routinely requested in all patients but this was subsequently stopped as post-NAC CT findings did not result in changes to the planned operative approach. Post-NAC imaging can be requested if required, based on the specifics of an individual case, thus keeping additional demands on radiology resources to a minimum. However, particularly during the early stages of NAC delivery by an MDT, a second pre-operative MDT review with updated imaging may provide reassurance and facilitate learning opportunities.

Following uncomplicated completion of NAC, and where the surgical plan has been discussed at the start of the pathway, patients can safely proceed directly to surgery without increased demands on surgical clinics.

## HISTOPATHOLOGY

### Key lesson: Surgeons must complete NAC details on the resection pathology request form

Assessment of tumour regression grade (TRG) following chemotherapy is essential to gauge treatment response and inform subsequent discussions regarding adjuvant chemotherapy – particularly in the absence of a post-NAC CT scan. Full clinical details of NAC are therefore required on the histopathology request form, which is usually completed by the surgical team.

## FOLLOW-UP

The postoperative pathway is not altered. Postoperative MDT discussion (with additional assessment of the TRG) and surgical outpatient review are arranged as usual, followed by oncology review to discuss the merits of adjuvant treatment.

## FUTURE DEVELOPMENTS AND PATIENT STRATIFICATION

Service developments under consideration include the provision of a joint surgical and oncological colon cancer clinic to streamline the pathway. The CNS role could be expanded, for example to initiate investigations to determine suitability for NAC (such as dihydropyrimidine dehydrogenase (DPYD) deficiency testing) prior to initial clinic review.

FOXROT-2 is currently recruiting at UK centres to determine whether dose-modified NAC may be beneficial for older,

frailer patients who were under-represented in the original trial. FOXROT-3 is also open to recruitment to explore whether escalation to triple-agent NAC with 5-fluorouracil, irinotecan and oxaliplatin – is of benefit to younger, fitter patients (ISRCTN83842641).

The strength of recently presented data from the NICHE-2 single-arm phase II trial of neoadjuvant nivolumab and ipilimumab for stage II-III dMMR colon cancer, in which 102 (95%) of 106 patients exhibited a major pathological response ( $\leq 10\%$  residual viable tumour cells),<sup>4</sup> indicates that neoadjuvant immunotherapy is likely to become standard of care for this patient subgroup in coming years. The NICHE-2 trial findings reinforce the need for rapid MMR testing to be made available at the point of diagnosis in all centres.

At present, RAS and BRAF mutation testing is frequently only performed when palliative therapy with antibody to epidermal growth factor receptor (anti-EGFR) is being considered. A subset of patients with tumours expressing wild-type RAS who were randomized to receive NAC with anti-EGFR (panitumumab) within FOXROT did not benefit from this regimen. Whether RAS and BRAF mutant subgroups benefitted equally from NAC in FOXROT is currently being explored. The current evidence therefore does not mandate bringing forward RAS and BRAF testing in the treatment pathway. However, this may change in future, and the FOXROT-4 trial, currently in set-up, will examine the role of BRAF targeted therapy (encorafenib plus cetuximab) in the neoadjuvant setting.

Multigene panel testing, is increasingly available. However, such multigene panels are not yet feasible within the narrow window for neoadjuvant therapy in most centres, and at present there are no widely available targeted therapies that can take advantage of additional genetic profiling. Translational work using the FOXROT biobank is being conducted with the aim of identifying additional molecular markers to improve patient selection, and outputs from this work may soon become of more practical use in the neoadjuvant setting as access and turnaround for multigene panels improves. Additionally, as subgroups of patients with MMR proficient disease are being found to benefit from neoadjuvant immunotherapy,<sup>5,6</sup> rapid assessment of novel predictive biomarkers developed from this work will soon become integral to the provision of quality care.

## CONCLUSION

Use of NAC for locally advanced colon cancer has been shown to improve surgical outcomes and longer term cancer outcomes. Provision of NAC requires some modifications to current treatment pathways but can be delivered with team working and without the requirement for additional resources.

## AUTHOR CONTRIBUTION

JS and AQ conceived of the article. Data was contributed by all authors and collated and analysed by CW and RF. CW and RF wrote the first draft of the manuscript which was then reviewed and revised by all authors.

## FUNDING INFORMATION

This work was not supported by any funding.

## CONFLICT OF INTEREST

All the authors confirm they have no conflicts of interest.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## ETHICS APPROVAL

Ethical approval was not required for this work.

## ORCID

Christopher JM Williams  <https://orcid.org/0000-0002-1574-653X>

Rebecca Fish  <https://orcid.org/0000-0002-4239-6993>

Nicholas West  <https://orcid.org/0000-0002-0346-6709>

Aaron J. Quyn  <https://orcid.org/0000-0002-4333-5658>

Jenny F Seligmann  <https://orcid.org/0000-0003-4379-6005>

## REFERENCES

1. Morton D, Magill M, Magill L, Handley K, Glasbey J, Glimelius B, et al.; FOxTROT Collaborative Group. Preoperative chemotherapy for operable colon cancer: Mature results of an international randomized controlled trial. *J Clin Oncol.* 2023 Jan 19;JCO2200046. <https://doi.org/10.1200/JCO.22.00046>. Online ahead of print. PMID: 36657089.
2. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair As a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol.* 2010;28:3219–26.
3. National Institute for Health and Care Excellence. Molecular testing strategies for Lynch syndrome in people with colorectal cancer: Diagnostics guideline [DG27]; 2017. [cited 2020 Oct 9]. Available from: <https://www.nice.org.uk/guidance/dg27/chapter/1-Recommendations>
4. Chalabi M, Verschoor YL, van den Berg J, Sikorska K, Beets G, Lent AV, et al. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. *Ann Oncol.* 2022;33:5808–69.
5. Chalabi M, Fanchi LF, Dijkstra KK, van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. *Nat Med.* 2020;26:566–76.
6. Avallone A, de Stefano A, Pace U, Catteau A, di Gennaro E, Tatangelo F, et al. Neoadjuvant nivolumab in early stage colorectal cancer. *Ann Oncol.* 2020;31:S449.

**How to cite this article:** Williams CJ, Fish R, Akerman L, West N, Tolan D, Quyn AJ, et al. Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways: Real-life experience of implementing FOxTROT. *Colorectal Dis.* 2023;25:352–356. <https://doi.org/10.1111/codi.16450>